[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center

PSMA-Activated Imaging Agents for Prostate Cancer

PSMA PET in Prostate Cancer.

Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography

Prostate cancer remains a major public health problem worldwide. Imaging plays an important role in the assessment of disease at all its clinical phases, including staging, restaging after definitive therapy, evaluation of therapy response, and prognostication. Positron emission tomography with a number of biologically targeted radiotracers has been demonstrated to have potential diagnostic and...

High dose radioiodine outpatient treatment: an initial experience in Thailand

Objective(s): The aim of this study was to determine whether high-dose radioactive iodine (Na131I) outpatient treatment of patients with thyroid carcinoma is a pragmatically safe approach, particularly for the safety of caregivers. Methods: A total of 79 patients completed the radiation-safety questionnaires prior to receiving high-dose radioactive iodine treatment. The questionnaire studied th...

Accuracy of the dose delivery in prostate cancer patients-using an electronic portal imaging device (EPID)

Background: To correct patient positioning errors (setup errors) during prostate cancer treatment using EPID and fiducial gold markers, to improve the accuracy of the dose delivery in these patients. Materials and Methods: Fifteen patients with localized prostate carcinoma after implantation of fiducial gold markers in their prostate gland underwent the five-field IMRT planning technique. The p...